Iterum Therapeutics plc
ITRM
$0.9966
-$0.0534-5.09%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -8.01% | -21.95% | 29.63% | 42.56% | -218.85% |
| Total Depreciation and Amortization | 3,162.50% | 0.00% | 14.29% | -98.41% | 0.92% |
| Total Amortization of Deferred Charges | -154.94% | 348.51% | 0.00% | -2.90% | -0.85% |
| Total Other Non-Cash Items | 422.67% | -18.05% | -4.92% | 52.28% | 106.38% |
| Change in Net Operating Assets | -1,845.21% | 97.90% | 55.14% | -238.04% | -138.67% |
| Cash from Operations | -59.28% | 60.47% | 48.34% | -1.87% | -38.62% |
| Capital Expenditure | -- | 100.00% | -- | -- | -100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -80.70% | 35.75% | -41.77% | -46.68% | 3,687.96% |
| Cash from Investing | -80.70% | 35.81% | -41.80% | -46.68% | 3,656.39% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 155.56% | 3,151.50% | -97.69% | 1,125.30% | 5,790.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 155.56% | 3,151.50% | -97.69% | 1,125.30% | 5,790.00% |
| Foreign Exchange rate Adjustments | 92.86% | -55.56% | 33.33% | -92.86% | 39.13% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 27.15% | 449.36% | -283.08% | 5.02% | 114.07% |